Loading...

We've got a brand new version of Simply Wall St! Try it out

Fluidigm

Nasdaq:FLDM
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
FLDM
Nasdaq
$165M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. The last earnings update was 5 days ago. More info.


Add to Portfolio Compare Print
  • Fluidigm has significant price volatility in the past 3 months.
FLDM Share Price and Events
7 Day Returns
-5.6%
NasdaqGS:FLDM
-1.5%
US Life Sciences
0.3%
US Market
1 Year Returns
-68.6%
NasdaqGS:FLDM
14.1%
US Life Sciences
12.5%
US Market
FLDM Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Fluidigm (FLDM) -5.6% -44.2% -62.9% -68.6% -60.6% -92.2%
US Life Sciences -1.5% 2.2% 2.1% 14.1% 83.2% 115.6%
US Market 0.3% 4.1% 5.6% 12.5% 39.4% 44.7%
1 Year Return vs Industry and Market
  • FLDM underperformed the Life Sciences industry which returned 14.1% over the past year.
  • FLDM underperformed the Market in United States of America which returned 12.5% over the past year.
Price Volatility
FLDM
Industry
5yr Volatility vs Market

Value

 Is Fluidigm undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Fluidigm. This is due to cash flow or dividend data being unavailable. The share price is $2.37.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Fluidigm's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Fluidigm's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:FLDM PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in USD $-1.12
NasdaqGS:FLDM Share Price ** NasdaqGS (2019-11-12) in USD $2.37
United States of America Life Sciences Industry PE Ratio Median Figure of 18 Publicly-Listed Life Sciences Companies 32.14x
United States of America Market PE Ratio Median Figure of 2,922 Publicly-Listed Companies 18.25x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Fluidigm.

NasdaqGS:FLDM PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:FLDM Share Price ÷ EPS (both in USD)

= 2.37 ÷ -1.12

-2.12x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Fluidigm is loss making, we can't compare its value to the US Life Sciences industry average.
  • Fluidigm is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Fluidigm's expected growth come at a high price?
Raw Data
NasdaqGS:FLDM PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.12x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
22.2%per year
United States of America Life Sciences Industry PEG Ratio Median Figure of 15 Publicly-Listed Life Sciences Companies 2.53x
United States of America Market PEG Ratio Median Figure of 2,023 Publicly-Listed Companies 1.46x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Fluidigm, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Fluidigm's assets?
Raw Data
NasdaqGS:FLDM PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in USD $2.34
NasdaqGS:FLDM Share Price * NasdaqGS (2019-11-12) in USD $2.37
United States of America Life Sciences Industry PB Ratio Median Figure of 36 Publicly-Listed Life Sciences Companies 4.52x
United States of America Market PB Ratio Median Figure of 5,066 Publicly-Listed Companies 1.74x
NasdaqGS:FLDM PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:FLDM Share Price ÷ Book Value per Share (both in USD)

= 2.37 ÷ 2.34

1.01x

* Primary Listing of Fluidigm.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Fluidigm is good value based on assets compared to the US Life Sciences industry average.
X
Value checks
We assess Fluidigm's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. Fluidigm has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Fluidigm expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
22.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Fluidigm expected to grow at an attractive rate?
  • Unable to compare Fluidigm's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Fluidigm's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Fluidigm's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:FLDM Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:FLDM Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 22.2%
NasdaqGS:FLDM Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 11.2%
United States of America Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 17.8%
United States of America Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average 7.6%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.2%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:FLDM Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:FLDM Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 191 -26 1
2022-12-31 161 -15 -30 2
2021-12-31 138 -35 -44 4
2020-12-31 125 -45 -50 5
2019-12-31 115 -41 -65 5
2019-11-13
NasdaqGS:FLDM Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-09-30 117 -30 -67
2019-06-30 120 -30 -69
2019-03-31 118 -29 -71
2018-12-31 113 -25 -59
2018-09-30 108 -24 -55
2018-06-30 104 -28 -56
2018-03-31 102 -32 -57
2017-12-31 102 -24 -61
2017-09-30 99 -35 -68
2017-06-30 97 -41 -72
2017-03-31 101 -40 -73
2016-12-31 104 -39 -76

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Fluidigm is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Fluidigm's revenue is expected to grow by 11.2% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:FLDM Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Fluidigm Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:FLDM Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.36 -0.36 -0.36 1.00
2022-12-31 -0.42 -0.38 -0.46 2.00
2021-12-31 -0.60 -0.51 -0.67 4.00
2020-12-31 -0.71 -0.62 -0.76 5.00
2019-12-31 -0.98 -0.95 -1.03 5.00
2019-11-13
NasdaqGS:FLDM Past Financials Data
Date (Data in USD Millions) EPS *
2019-09-30 -1.12
2019-06-30 -1.32
2019-03-31 -1.60
2018-12-31 -1.49
2018-09-30 -1.40
2018-06-30 -1.48
2018-03-31 -1.60
2017-12-31 -1.84
2017-09-30 -2.22
2017-06-30 -2.45
2017-03-31 -2.52
2016-12-31 -2.62

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Fluidigm will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Fluidigm's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Fluidigm has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Fluidigm performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Fluidigm's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Fluidigm does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Fluidigm's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Fluidigm's 1-year growth to the US Life Sciences industry average as it is not currently profitable.
Earnings and Revenue History
Fluidigm's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Fluidigm Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:FLDM Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 117.13 -66.88 86.66 31.32
2019-06-30 119.60 -68.74 86.95 31.63
2019-03-31 117.83 -71.23 83.80 31.15
2018-12-31 112.96 -59.01 79.78 30.03
2018-09-30 108.38 -54.70 73.68 52.90
2018-06-30 104.17 -55.89 73.76 45.47
2018-03-31 101.65 -56.58 75.75 38.08
2017-12-31 101.94 -60.54 79.52 30.83
2017-09-30 99.28 -67.77 86.42
2017-06-30 96.72 -71.62 87.44
2017-03-31 100.98 -73.30 90.31
2016-12-31 104.45 -75.99 93.21 38.42
2016-09-30 110.08 -71.17 92.53
2016-06-30 116.54 -60.65 90.96
2016-03-31 116.99 -57.27 88.34
2015-12-31 114.71 -53.32 82.96
2015-09-30 117.48 -51.38 78.41
2015-06-30 118.47 -55.90 78.53
2015-03-31 117.46 -53.35 75.16
2014-12-31 116.46 -52.83 71.32
2014-09-30 103.85 -46.53 66.06
2014-06-30 92.50 -37.03 58.48
2014-03-31 82.37 -28.39 52.22
2013-12-31 71.18 -16.53 48.41
2013-09-30 65.96 -15.49 45.39
2013-06-30 60.46 -15.35 42.40
2013-03-31 55.92 -15.89 40.22
2012-12-31 52.33 -19.02 38.48

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Fluidigm has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Fluidigm has efficiently used its assets last year compared to the US Life Sciences industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Fluidigm improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Fluidigm's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Fluidigm has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Fluidigm's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Fluidigm's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Fluidigm is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Fluidigm's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Fluidigm's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Fluidigm Company Filings, last reported 1 month ago.

NasdaqGS:FLDM Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 162.61 49.85 62.76
2019-06-30 172.64 49.83 68.86
2019-03-31 182.25 49.78 75.13
2018-12-31 72.12 172.06 95.40
2018-09-30 22.41 169.35 35.83
2018-06-30 34.83 166.76 40.42
2018-03-31 48.57 164.16 47.25
2017-12-31 30.94 195.24 63.14
2017-09-30 39.07 195.17 62.37
2017-06-30 23.94 195.09 42.03
2017-03-31 38.50 195.02 50.28
2016-12-31 53.23 194.95 59.43
2016-09-30 67.97 194.88 71.25
2016-06-30 84.26 194.81 86.41
2016-03-31 98.98 194.74 95.22
2015-12-31 114.90 194.67 94.97
2015-09-30 124.13 195.63 97.07
2015-06-30 133.22 195.57 99.93
2015-03-31 142.45 195.51 116.41
2014-12-31 150.42 195.46 115.30
2014-09-30 154.56 195.40 95.26
2014-06-30 161.83 195.34 94.74
2014-03-31 167.43 195.25 143.15
2013-12-31 96.41 0.00 84.34
2013-09-30 97.01 0.00 63.68
2013-06-30 98.39 0.00 60.43
2013-03-31 100.12 0.00 79.57
2012-12-31 100.66 0.00 80.01
  • Fluidigm's level of debt (30.7%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (126.5% vs 30.7% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Fluidigm has sufficient cash runway for 1.9 years based on current free cash flow.
  • Fluidigm has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of -18% each year.
X
Financial health checks
We assess Fluidigm's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Fluidigm has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Fluidigm's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Fluidigm dividends. Estimated to be 0% next year.
If you bought $2,000 of Fluidigm shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Fluidigm's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Fluidigm's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:FLDM Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
United States of America Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 0.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1948 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:FLDM Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00
2019-11-13

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Fluidigm has not reported any payouts.
  • Unable to verify if Fluidigm's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Fluidigm's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Fluidigm has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Fluidigm's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Fluidigm's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Fluidigm afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Fluidigm has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Fluidigm's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Chris Linthwaite
COMPENSATION $2,585,208
AGE 46
TENURE AS CEO 3.1 years
CEO Bio

Mr. Stephen Christopher Linthwaite, also known as Chris, has been the President of Fluidigm Corporation since August 4, 2016. Mr. Linthwaite has been the Chief Executive Officer of Fluidigm Corporation since October 19, 2016. Mr. Linthwaite served as Chief Operating Officer of Fluidigm Corporation since August 4, 2016 until October 28, 2016. Mr. Linthwaite served as President of the Genetic Sciences Division at Thermo Fisher Scientific and the President of the BioProduction Division at Life Technologies. From August 2003 to April 2016, Mr. Linthwaite held various managerial positions at Thermo Fisher Scientific Inc., a life sciences company, and prior to its acquisition by Thermo Fisher, at Life Technologies Corporation, a life sciences company, including president, genetic sciences division, from December 2014 to April 2016, president, genetic analysis platform, from September 2011 to December 2014, and various other managerial positions at Invitrogen prior to the creation of Life Technologies through a merger of Invitrogen and Applied Biosystems. Prior to joining Invitrogen, Mr. Linthwaite held various strategic consulting roles. Mr. Linthwaite served on the board of directors of Claritas Genomics, Inc. from December 2014 to April 2016. He has been a Director of Fluidigm Corporation since October 19, 2016. Mr. Linthwaite received a M.B.A. from the University of Virginia (Darden) School of Business and a B.A. in Foreign Affairs from the University of Virginia. Prior to business school, Mr. Linthwaite served on active duty in the U.S. Army as an armor officer.

CEO Compensation
  • Chris's compensation has increased whilst company is loss making.
  • Chris's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Fluidigm management team in years:

2.7
Average Tenure
45.5
Average Age
  • The tenure for the Fluidigm management team is about average.
Management Team

Chris Linthwaite

TITLE
President
COMPENSATION
$3M
AGE
46
TENURE
3.1 yrs

Vikram Jog

TITLE
CFO & Principal Accounting Officer
COMPENSATION
$1M
AGE
63
TENURE
11.8 yrs

Brad Kreger

TITLE
Senior Vice President of Global Operations
COMPENSATION
$995K
AGE
44
TENURE
1.6 yrs

Nick Khadder

TITLE
Senior VP
COMPENSATION
$1M
AGE
45
TENURE
3.4 yrs

Steve Quake

TITLE
Co-Founder & Chairman of Advisory Board
TENURE
20.8 yrs

Andrew Quong

TITLE
Chief Science Officer
TENURE
0.4 yrs

Agnes Lee

TITLE
Vice President of Investor Relations

Mark Spearman

TITLE
Senior Director of Corporate Communications

Angela Peters

TITLE
Vice President of Global Human Resources
TENURE
2.3 yrs

Colin McCracken

TITLE
Chief Commercial Officer
TENURE
0.7 yrs
Board of Directors Tenure

Average tenure and age of the Fluidigm board of directors in years:

12.9
Average Tenure
64.5
Average Age
  • The average tenure for the Fluidigm board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Sam Colella

TITLE
Chairman of the Board
COMPENSATION
$165K
AGE
79
TENURE
19.3 yrs

Chris Linthwaite

TITLE
President
COMPENSATION
$3M
AGE
46
TENURE
3.1 yrs

Steve Quake

TITLE
Co-Founder & Chairman of Advisory Board

Pat Jones

TITLE
Independent Director
COMPENSATION
$128K
AGE
75
TENURE
8.7 yrs

Nicolas Barthelemy

TITLE
Independent Director
COMPENSATION
$125K
AGE
53
TENURE
2.7 yrs

Carlos Paya

TITLE
Independent Director
COMPENSATION
$113K
AGE
60
TENURE
2.7 yrs

Richard Zare

TITLE
Member of Advisory Board
TENURE
18.9 yrs

Howard Shapiro

TITLE
Member of Advisory Board
TENURE
19.9 yrs

James Berger

TITLE
Member of Advisory Board
TENURE
17.4 yrs

Frank McCormick

TITLE
Member of Advisory Board
AGE
69
TENURE
12.9 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Fluidigm individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
19. Sep 19 Sell Levin Easterly Partners LLC Company 17. Sep 19 17. Sep 19 -577,197 $5.40 $-3,116,864
13. Sep 19 Sell Levin Easterly Partners LLC Company 11. Sep 19 11. Sep 19 -11,545 $5.56 $-64,112
29. Aug 19 Buy Samuel Colella Individual 27. Aug 19 27. Aug 19 2,000 $5.19 $10,372
27. Aug 19 Buy Stephen Linthwaite Individual 23. Aug 19 23. Aug 19 4,000 $5.52 $22,077
15. Aug 19 Sell Levin Easterly Partners LLC Company 13. Aug 19 13. Aug 19 -151,011 $7.01 $-1,059,282
12. Aug 19 Buy Samuel Colella Individual 08. Aug 19 08. Aug 19 1,000 $6.65 $6,653
12. Aug 19 Sell Levin Easterly Partners LLC Company 07. Aug 19 07. Aug 19 -129,237 $6.90 $-892,060
09. Aug 19 Buy Samuel Colella Individual 06. Aug 19 07. Aug 19 9,000 $7.02 $63,040
05. Aug 19 Sell Levin Easterly Partners LLC Company 01. Aug 19 01. Aug 19 -1,629 $12.25 $-19,956
29. Jul 19 Sell Levin Easterly Partners LLC Company 25. Jul 19 29. Jul 19 -287,972 $11.97 $-3,435,242
24. Jul 19 Sell Levin Easterly Partners LLC Company 22. Jul 19 24. Jul 19 -108,123 $11.78 $-1,257,320
19. Jul 19 Sell Levin Easterly Partners LLC Company 17. Jul 19 19. Jul 19 -398,068 $11.50 $-4,553,604
02. Jul 19 Sell Levin Easterly Partners LLC Company 28. Jun 19 01. Jul 19 -186,759 $12.37 $-2,298,258
27. Jun 19 Sell Levin Easterly Partners LLC Company 24. Jun 19 25. Jun 19 -217,148 $12.35 $-2,666,660
26. Dec 18 Buy Levin Capital Strategies, L.P. Company 20. Dec 18 24. Dec 18 661 $7.79 $4,935
20. Dec 18 Buy Levin Capital Strategies, L.P. Company 18. Dec 18 19. Dec 18 164 $7.86 $1,284
18. Dec 18 Buy Levin Capital Strategies, L.P. Company 14. Dec 18 14. Dec 18 41 $7.81 $320
14. Dec 18 Buy Levin Capital Strategies, L.P. Company 12. Dec 18 12. Dec 18 1,000,000 $6.75 $6,750,000
11. Dec 18 Buy Levin Capital Strategies, L.P. Company 07. Dec 18 10. Dec 18 35,033 $7.95 $270,462
16. Nov 18 Buy Levin Capital Strategies, L.P. Company 14. Nov 18 14. Nov 18 47,768 $7.55 $360,696
X
Management checks
We assess Fluidigm's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Fluidigm has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Is Fluidigm (NASDAQ:FLDM) Using Debt In A Risky Way?

We note that Fluidigm Corporation (NASDAQ:FLDM) does have debt on its balance sheet. … NasdaqGS:FLDM Historical Debt, September 2nd 2019 A Look At Fluidigm's Liabilities We can see from the most recent balance sheet that Fluidigm had liabilities of US$37.3m falling due within a year, and liabilities of US$73.8m due beyond that. … Despite its noteworthy liabilities, Fluidigm boasts net cash, so it's fair to say it does not have a heavy debt load!

Simply Wall St -

Trade Alert: The Chairman of the Board Of Fluidigm Corporation (NASDAQ:FLDM), Samuel Colella, Has Just Spent US$63k Buying Shares

View our latest analysis for Fluidigm Fluidigm Insider Transactions Over The Last Year In fact, the recent purchase by Samuel Colella was the biggest purchase of Fluidigm shares made by an insider individual in the last twelve months, according to our records. … As a general rule, we feel more positive about a stock when an insider has bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price. … On this analysis the only slight negative we see is the fairly low (overall) insider ownership; their transactions suggest that they are quite positive on Fluidigm stock.

Simply Wall St -

Here's What We Think About Fluidigm Corporation's (NASDAQ:FLDM) CEO Pay

Check out our latest analysis for Fluidigm How Does Chris Linthwaite's Compensation Compare With Similar Sized Companies? … At the time of writing our data says that Fluidigm Corporation has a market cap of US$800m, and is paying total annual CEO compensation of US$2.6m. … With a total shareholder return of 16% over three years, Fluidigm Corporation shareholders would, in general, be reasonably content.

Simply Wall St -

Did Changing Sentiment Drive Fluidigm's Share Price Down A Painful 77%?

Fluidigm isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … When a company doesn't make profits, we'd generally expect to see good revenue growth. … That's not a very high growth rate considering it doesn't make profits.

Simply Wall St -

Can We See Significant Institutional Ownership On The Fluidigm Corporation (NASDAQ:FLDM) Share Register?

If you want to know who really controls Fluidigm Corporation (NASDAQ:FLDM), then you'll have to look at the makeup of its share registry. … Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … Fluidigm is a smaller company with a market capitalization of US$379m, so it may still be flying under the radar of many institutional investors.

Simply Wall St -

Fluidigm Corporation (NASDAQ:FLDM): What Are The Future Prospects?

In March 2018, Fluidigm Corporation (NASDAQ:FLDM) announced its earnings update. … with earnings expected to grow by 0.44% in the upcoming year … the past 5-year average growth rate of -21.01%

Simply Wall St -

Is Fluidigm Corporation's (NASDAQ:FLDM) Balance Sheet A Threat To Its Future?

While small-cap stocks, such as Fluidigm Corporation (NASDAQ:FLDM) with its market cap of US$220.27m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn.

Simply Wall St -

When Will Fluidigm Corporation (NASDAQ:FLDM) Turn A Profit?

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. … The US$196.53m market-cap posted a loss in its most recent financial year of -US$60.53m and a latest trailing-twelve-month loss of -US$56.58m shrinking the gap between loss and breakeven? … Expectation from Life Sciences analysts is FLDM is on the verge of breakeven.

Simply Wall St -

Is There Now An Opportunity In Fluidigm Corporation (NASDAQ:FLDM)?

Fluidigm Corporation (NASDAQ:FLDM), a life sciences company based in United States, saw significant share price volatility over the past couple of months on the NasdaqGS, rising to the highs of $7.81 and falling to the lows of $5.46. … The stock’s ratio of 4.64x is currently trading slightly above its industry peers’ ratio of 3.24x, which means if you buy Fluidigm today, you’d be paying a relatively fair price for it. … And if you believe that Fluidigm should be trading at this level in the long run, there’s only an insignificant downside when the price falls to its real value.

Simply Wall St -

Is Fluidigm Corporation (NASDAQ:FLDM) A Financially Sound Company?

How does FLDM’s operating cash flow stack up against its debt? … At this stable level of debt, FLDM's cash and short-term investments stands at US$63.14M for investing into the business. … Maintaining a high level of debt, while revenues are still below costs, can be dangerous as liquidity tends to dry up in unexpected downturns.Next Steps: FLDM’s debt and cash flow levels indicate room for improvement.

Simply Wall St -

Company Info

Description

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. It sells instruments and consumables, including IFCs, assays, and reagents to academic institutions, clinical research laboratories, and contract research organizations, as well as biopharmaceutical, biotechnology, and agricultural biotechnology companies. The company sells its products to academic institutions, life sciences, and clinical research laboratories that conduct research, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.

Details
Name: Fluidigm Corporation
FLDM
Exchange: NasdaqGS
Founded: 1999
$164,868,834
69,564,909
Website: http://www.fluidigm.com
Address: Fluidigm Corporation
7000 Shoreline Court,
Suite 100,
South San Francisco,
California, 94080,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS FLDM Common Stock Nasdaq Global Select US USD 10. Feb 2011
DB FLB Common Stock Deutsche Boerse AG DE EUR 10. Feb 2011
Number of employees
Current staff
Staff numbers
535
Fluidigm employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/13 00:13
End of day share price update: 2019/11/12 00:00
Last estimates confirmation: 2019/11/07
Last earnings filing: 2019/11/08
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.